Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility

Simply Wall St.01:06

AdvertisementCollegium Pharmaceutical overview Collegium Pharmaceutical (COLL) has drawn attention after recent trading showed a 2.4% daily decline and a 21% drop over the past month, contrasting with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621742745?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-23 01:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621742745","market":"nz","top_or_hot":-1,"title":"Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementCollegium Pharmaceutical overview Collegium Pharmaceutical (COLL) has drawn attention after recent trading showed a 2.4% daily decline and a 21% drop over the past month, contrasting with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/collegium-pharmaceutical-coll-valuation-check-after-recent-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 01:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/collegium-pharmaceutical-coll-valuation-check-after-recent-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementCollegium Pharmaceutical overview Collegium Pharmaceutical (COLL) has drawn attention after recent trading showed a 2.4% daily decline and a 21% drop over the past month, contrasting with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/collegium-pharmaceutical-coll-valuation-check-after-recent-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/collegium-pharmaceutical-coll-valuation-check-after-recent-s","article_id":"2621742745","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/collegium-pharmaceutical-coll-valuation-check-after-recent-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621742745","pubTimestamp":1774199161,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Collegium Pharmaceutical overview\nCollegium Pharmaceutical (COLL) has drawn attention after recent trading showed a 2.4% daily decline and a 21% drop over the past month, contrasting with a 17.9% total return over the past year.\nSee our latest analysis for Collegium Pharmaceutical.\nThe recent 21.2% 1 month share price decline, alongside a weaker 22.2% year to date share price return, contrasts with a stronger 17.9% 1 year total shareholder return. This suggests longer term holders have still...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","COLL":"Collegium Pharmaceutical, Inc."},"translate_title":"Collegium Pharmaceutical(COLL)近期股价波动后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COLL":1.5},"content_text":"AdvertisementCollegium Pharmaceutical overview Collegium Pharmaceutical (COLL) has drawn attention after recent trading showed a 2.4% daily decline and a 21% drop over the past month, contrasting with a 17.9% total return over the past year. See our latest analysis for Collegium Pharmaceutical. The recent 21.2% 1 month share price decline, alongside a weaker 22.2% year to date share price return, contrasts with a stronger 17.9% 1 year total shareholder return. This suggests longer term holders have still fared better than recent buyers. If recent volatility has you comparing opportunities, this is a good moment to broaden your watchlist and check out 20 top founder-led companies With Collegium showing mixed recent returns but trading at a level that implies a potential intrinsic discount, investors now face a key question: is today’s price a genuine opening, or is the market already factoring in future growth? Most Popular Narrative: 34.2% Undervalued Collegium Pharmaceutical's most followed narrative pegs fair value at $53.83 per share versus the last close of $35.44, framing a sizeable valuation gap for investors to assess.  The company's differentiated pain portfolio, notably with products featuring proprietary abuse-deterrent and extended-release technologies (e.g., Xtampza ER's DETERx platform), is supported by industry and regulatory trends that increasingly favor safer opioid options, which may enhance market share and pricing power and sustain net margins as regulatory emphasis on abuse deterrence grows.  Read the complete narrative. Want to understand why this story supports a higher fair value? The core assumptions blend slower top line expectations with meaningfully higher margins and a different earnings multiple than today. The tension between these inputs is what drives the 34.2% discount. Result: Fair Value of $53.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the picture could change if patent expiries invite meaningful generic competition, or if higher operating costs are not offset by the expected margin improvements. Find out about the key risks to this Collegium Pharmaceutical narrative. Another way to look at value The first narrative leans heavily on future cash flows and fair value at $53.83. On simple earnings, though, Collegium trades on a P/E of 17.9x, slightly above the US Pharmaceuticals average of 16.6x but well below a peer average of 38.1x and an estimated fair ratio of 23.4x. That split hints at both valuation risk and potential upside if sentiment shifts. Which reference point do you trust most? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:COLL P/E Ratio as at Mar 2026Next Steps Mixed messages on value and risk so far? Take a closer look at the numbers and sentiment yourself, then weigh up the 3 key rewards and 2 important warning signs. Ready to find your next idea? Collegium might be on your radar, but your portfolio deserves more than one story. Use focused stock lists to spot opportunities before they get crowded.  Target steady compounding by reviewing companies that appear priced below their estimated worth with the 53 high quality undervalued stocks. Prioritise resilience by checking businesses that pair strong finances with measured risk using the 68 resilient stocks with low risk scores. Get ahead of the crowd by scanning a screener containing 26 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621742745","isCrawlerRequest":true}